Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Dr Paul Pfeffer
+44 (0)2034165000
Paul.pfeffer1@nhs.net


Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Investigating the effect of the pro-inflammatory messenger interleukin-5 on antibody-secreting immune cells in the nose

Investigating the effect of the pro-inflammatory messenger interleukin-5 on antibody-secreting immune cells in the nose

Recruiting

Open to: All Genders

Age: Adult

Medical Conditions

Nasal polyps


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


In patients with asthma, nasal polyps and other similar diseases, the chemical messenger interleukin-5 (IL-5) in the body is known to have an important role in causing disease - blocking the IL-5 message improves disease control and can lead to clinical remission. IL-5 is often thought to work through its actions on a type of immune cell called eosinophils, but there is evidence it may also have important actions on other types of immune cells. In particular it appears to have actions on antibody-producing B cells. This study will investigate how IL-5 affects antibody expression by B cells in the nose using samples collected from patients undergoing removal of tissue samples from the nose for clinical reasons.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

14 Mar 2024 31 Dec 2025

The study involves donating to the research project the nasal samples that are being removed at clinically planned surgery. The study team will also collect some clinical data, a sample of blood and a sample of the fluid inside the nose using a special sponge (certain NHS sites only).


Patients aged 18 years and over having surgery to remove nasal tissue for clinical reasons at relevant NHS sites

You can take part if:



You may not be able to take part if:


1. Inability to give consent2. Previous rituximab treatment (ever)3. Chemotherapy with preceding 6 months4. Cystic fibrosis5. Pregnancy or breastfeeding6. Known current COVID infection/TB infection


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Royal London Hospital
    Whitechapel Road
    London
    E1 1FR
  • UCLH
    250 Euston Road
    London
    NW1 2PQ
  • Guys Hospital
    Guys Hospital Great Maze Pond
    London
    SE1 9RT
  • Homerton Hospital
    Homerton Row
    London
    E9 6SR

There are minimal risks from participating as the major study activity is the donation to research of the nasal samples being removed from the nose by surgeons as part of planned clinical care. The study will not directly benefit participating patients but will help develop better treatments for patients with these conditions.


The study is sponsored by Queen Mary University of London and funded by GlaxoSmithKline; Grant Codes: 220761.




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: ISRCTN16169610

Or CPMS 60796

Last updated 11 March 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.